Citigroup’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.55K | Buy |
4,012
+1,201
| +43% | +$3.31K | ﹤0.01% | 5247 |
|
|
2026
Q1 | $7.73K | Buy |
2,811
+10
| +0.4% | +$31 | ﹤0.01% | 5138 |
|
|
2025
Q4 | $8.79K | Buy |
2,801
+870
| +45% | +$2.74K | ﹤0.01% | 5102 |
|
|
2025
Q3 | $5.58K | Buy |
1,931
+16
| +0.8% | +$36 | ﹤0.01% | 5203 |
|
|
2025
Q2 | $3.89K | Buy |
1,915
+476
| +33% | +$828 | ﹤0.01% | 5306 |
|
|
2025
Q1 | $2.69K | Sell |
1,439
-1,288
| -47% | -$3.25K | ﹤0.01% | 5331 |
|
|
2024
Q4 | $7.36K | Buy |
2,727
+971
| +55% | +$3.03K | ﹤0.01% | 5420 |
|
|
2024
Q3 | $6.64K | Sell |
1,756
-340
| -16% | -$1.19K | ﹤0.01% | 5331 |
|
|
2024
Q2 | $8.36K | Buy |
2,096
+1,786
| +576% | +$5.91K | ﹤0.01% | 5183 |
|
|
2024
Q1 | $918 | Sell |
310
-1,204
| -80% | -$4.32K | ﹤0.01% | 5433 |
|
|
2023
Q4 | $7.57K | Buy |
+1,514
| New | +$4.87K | ﹤0.01% | 5264 |
|
|
2023
Q2 | – | Sell |
-870,179
| Closed | -$2.04M | – | 5556 |
|
|
2023
Q1 | $2.04M | Buy |
+870,179
| New | +$2.01M | ﹤0.01% | 2015 |
|
|
2022
Q4 | – | Sell |
-918
| Closed | -$3K | – | 5753 |
|
|
2022
Q3 | $3K | Sell |
918
-285
| -24% | -$898 | ﹤0.01% | 5352 |
|
|
2022
Q2 | $4K | Sell |
1,203
-497
| -29% | -$1.7K | ﹤0.01% | 5656 |
|
|
2022
Q1 | $7K | Sell |
1,700
-707
| -29% | -$3.06K | ﹤0.01% | 5666 |
|
|
2021
Q4 | $12K | Sell |
2,407
-1,890
| -44% | -$11K | ﹤0.01% | 5519 |
|
|
2021
Q3 | $29K | Sell |
4,297
-108
| -2% | -$773 | ﹤0.01% | 5042 |
|
|
2021
Q2 | $35K | Buy |
4,405
+3,034
| +221% | +$21K | ﹤0.01% | 4978 |
|
|
2021
Q1 | $10K | Sell |
1,371
-787
| -36% | -$5.62K | ﹤0.01% | 5618 |
|
|
2020
Q4 | $11K | Sell |
2,158
-2,069
| -49% | -$10.6K | ﹤0.01% | 6915 |
|
|
2020
Q3 | $21K | Sell |
4,227
-149
| -3% | -$1.07K | ﹤0.01% | 6156 |
|
|
2020
Q2 | $29K | Buy |
4,376
+220
| +5% | +$1.6K | ﹤0.01% | 6335 |
|
|
2020
Q1 | $29K | Sell |
4,156
-1,083
| -21% | -$8.46K | ﹤0.01% | 6425 |
|
|
2019
Q4 | $45K | Buy |
5,239
+3,462
| +195% | +$23.1K | ﹤0.01% | 6384 |
|
|
2019
Q3 | $9K | Buy |
1,777
+207
| +13% | +$1.11K | ﹤0.01% | 7106 |
|
|
2019
Q2 | $9K | Buy |
1,570
+603
| +62% | +$3.07K | ﹤0.01% | 7327 |
|
|
2019
Q1 | $5K | Buy |
+967
| New | +$6.15K | ﹤0.01% | 7405 |
|
|
2018
Q2 | – | Sell |
-4,918
| Closed | -$51K | – | 7585 |
|
|
2018
Q1 | $51K | Sell |
4,918
-600
| -11% | -$7.3K | ﹤0.01% | 6147 |
|
|
2017
Q4 | $71K | Hold |
5,518
| – | – | ﹤0.01% | 5914 |
|
|
2017
Q3 | $62K | Hold |
5,518
| – | – | ﹤0.01% | 5878 |
|
|
2017
Q2 | $49K | Buy |
+5,518
| New | +$51.1K | ﹤0.01% | 5802 |
|
Other funds holding ACIU
Citigroup's ACIU Position: Q2 2026 in Review
Citigroup increased its AC Immune (ACIU) stake by 43% in Q2 2026, buying an estimated $3.31K and bringing the position to 4,012 shares worth $9.55K. The position accounts for ﹤0.01% of the portfolio, ranked #5247.
Citigroup first reported a position in ACIU in Q2 2017 and has held it in 31 quarters since. The position peaked at $2.04M in Q1 2023. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Citigroup held 4,012 shares of AC Immune worth $9.55K as of Q2 2026.
- Citigroup bought 1,201 AC Immune shares in Q2 2026, an estimated $3.31K.
- AC Immune made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5247 holding.
- Citigroup first reported a position in AC Immune in Q2 2017 and has held it in 31 quarters since.
- Citigroup's AC Immune position peaked at $2.04M in Q1 2023.
- 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.